Canada’s Drug Agency | Drugs, Health Technologies and Systems.
Canada’s Drug Agency | Drugs, Health Technologies and Systems.

baricitinib

Details

Files
Generic Name:
baricitinib
Project Status:
Active
Therapeutic Area:
Alopecia areata, severe
Manufacturer:
Eli Lilly Canada Inc.
Call for patient/clinician input open:
Brand Name:
Olumiant
Project Line:
Reimbursement Review
Project Number:
SR0843-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Performance Metric:
Achieved
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the treatment of adult patients with severe alopecia areata.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
​For the treatment of adult patients with severe alopecia areata.
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Key Milestones2
Call for patient/clinician input open22-Jan-24
Call for patient/clinician input closed19-Mar-24
Clarification:

- Patient input submission received from Canadian Alopecia Areata Foundation

Submission received04-Mar-24
Submission accepted19-Mar-24
Review initiated20-Mar-24
Draft Canada's Drug Agency review report(s) provided to sponsor for comment07-Jun-24
Deadline for sponsors comments18-Jun-24
Canada's Drug Agency review report(s) and responses to comments provided to sponsor12-Jul-24
Expert committee meeting (initial)24-Jul-24
Draft recommendation issued to sponsor07-Aug-24
Draft recommendation posted for stakeholder feedback15-Aug-24
End of feedback period29-Aug-24
Final recommendation issued to sponsor and drug plans13-Sep-24
Final recommendation posted02-Oct-24
Deadline for sponsor to submit redaction requests on draft Canada's Drug Agency review report(s)27-Sep-24
Canada's Drug Agency review report(s) posted-

Files

Recommendation and Reasons View PDF
Patient and Clinician Group input View PDF
Last Updated : October 22, 2024